Plus therapeutics showcases new interim respect-gbm phase 2 trial data at the 2024 congress of neurological surgeons annual meeting

Austin, texas, sept. 18, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, will present data at the 2024 congress of neurological surgeons (cns) annual meeting september 28 - october 2, in houston, texas.
PSTV Ratings Summary
PSTV Quant Ranking